AstraZeneca Overturns $107.5 Million Jury Verdict in Patent Dispute with Wyeth LLC

In a significant legal triumph, AstraZeneca Pharmaceuticals LP successfully overturned a $107.5 million jury verdict by prevailing on the argument that the patents-in-suit held by Wyeth LLC, a subsidiary of Pfizer, were invalid. The jury had initially ruled in May that AstraZeneca had infringed on two of Wyeth’s patents related to unit dosage. However, AstraZeneca’s posttrial arguments in the U.S. District Court for the District of Delaware led to an opposite determination, erasing the previous verdict. Further details on this case can be found here.